Get the Stockscreener App
5.13
0.97%
-0.05
After Hours:
5.17
0.04
+0.78%
Imunon Inc stock is traded at $5.13, with a volume of 39,428.
It is down -0.97% in the last 24 hours and down -13.49% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$5.18
Open:
$5.17
24h Volume:
39,428
Relative Volume:
0.18
Market Cap:
$12.52M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-2.7143
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+0.39%
1M Performance:
-13.49%
6M Performance:
-62.54%
1Y Performance:
-62.90%
1-Day Range:
$5.03
$5.2313
1-Week Range:
$5.02
$5.35
52-Week Range:
$4.70
$41.22
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
5.13 | 13.06M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Stock (IMNN) Latest News
How Imunon Inc. stock responds to policy changesJuly 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
Can Imunon Inc. (CBO) stock surprise markets with earningsProduct Launch & Daily Entry Point Alerts - newser.com
What market sentiment indicators show for Imunon Inc. (CBO) stockEarnings Recap Summary & Proven Capital Preservation Methods - newser.com
Applying Wyckoff theory to Imunon Inc. stockDollar Strength & Consistent Return Investment Signals - newser.com
Will Imunon Inc. (CBO) stock attract long term capital inflowsJuly 2025 Retail & Weekly Momentum Picks - newser.com
What analysts say about Imunon Inc CBO stockInsider Buying Signals & Free Explosive Portfolio Gains - earlytimes.in
What earnings revisions data tells us about Imunon Inc.Weekly Stock Report & Free High Return Stock Watch Alerts - newser.com
Why Imunon Inc. stock attracts high net worth investorsStop Loss & Weekly Top Gainers Trade List - newser.com
Custom strategy builders for tracking Imunon Inc.2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Real time alert setup for Imunon Inc. performanceMarket Performance Summary & Growth Focused Entry Reports - newser.com
Is Imunon Inc CBO a good long term investmentGlobal Market Influence & Free Stop-Loss Planning for Your Portfolio - earlytimes.in
What drives Imunon Inc stock priceInflation Impact on Stocks & Superior Capital Trading Plans - earlytimes.in
What analysts say about Imunon Inc stockSwing Trading Watchlist & Low Entry Capital Stocks - Early Times
Imunon to present translational data from Phase 2 OVATION 2 Study of IMNN-001 - MSN
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer - Yahoo Finance
IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment… - Yahoo Finance
IMUNON reports positive data from ovarian cancer immunotherapy study By Investing.com - Investing.com Nigeria
IMUNON reports positive data from ovarian cancer immunotherapy study - Investing.com India
Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits - TipRanks
Imunon (IMNN) Shares New Positive Data from Phase 2 OVATION 2 St - GuruFocus
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift - The Manila Times
IMUNON Presents IMNN-001 Phase 2 Translational Data in - GlobeNewswire
13-Month Survival Extension: IMUNON's Novel Immunotherapy Shows Promise in Advanced Ovarian Cancer Study - Stock Titan
Guidance Update: Is Imunon Inc a defensive stock2025 Buyback Activity & Risk Controlled Daily Plans - خودرو بانک
IMUNON to present new data on ovarian cancer therapy at AACR conference By Investing.com - Investing.com South Africa
Aug Wrap: Should I invest in Imunon Inc before earnings2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - خودرو بانک
IMUNON to present new data on ovarian cancer therapy at AACR conference - Investing.com India
Levels Update: Will Imunon Inc outperform small cap indexesJuly 2025 Catalysts & Long-Term Growth Plans - خودرو بانک
Trading Recap: Will Imunon Inc outperform its industry peers2025 Technical Patterns & Growth Focused Entry Reports - khodrobank.com
Big Money Moves: Can Imunon Inc. stock outperform in a bear market2025 Growth vs Value & Consistent Profit Trade Alerts - خودرو بانک
IMUNON (IMNN) to Present New Data on Innovative Ovarian Cancer T - GuruFocus
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research - The Manila Times
IMUNON Advances IMNN-001 in Pivotal Phase 3 Trial for Advanced Ovarian Cancer, New Data Presented at AACR Conference - Quiver Quantitative
IMUNON to Present New Translational Data of IMNN-001 - GlobeNewswire
First Effective IL-12 Gene Therapy for Advanced Ovarian Cancer: IMUNON's IMNN-001 Shows Survival Benefits - Stock Titan
Volume Report: What is Imunon Incs P E ratio telling usTrend Reversal & Community Consensus Trade Alerts - khodrobank.com
Market Moves: Can Imunon Inc continue delivering strong returnsWeekly Profit Analysis & Long Hold Capital Preservation Plans - خودرو بانک
Swing Trade: Can Lucid Group Inc. reach all time highs this yearWeekly Investment Recap & Real-Time Chart Pattern Alerts - خودرو بانک
Street Watch: Can San Juan Basin Royalty Trust expand its profit marginsInsider Selling & Long-Term Growth Stock Strategies - خودرو بانک
Momentum Shift: Can Imunon Inc. expand into new marketsChart Signals & Growth Focused Stock Pick Reports - خودرو بانک
Momentum Shift: Is Imunon Inc. trading at a discountJuly 2025 Patterns & High Accuracy Swing Trade Signals - khodrobank.com
Shorts Report: Will Imunon Inc. benefit from rate cutsJuly 2025 Macro Moves & Weekly Setup with ROI Potential - خودرو بانک
Winners Losers: Is Imunon Inc likely to announce a buybackJuly 2025 Short Interest & Growth Oriented Trading Recommendations - خودرو بانک
Options Flow: Can Imunon Inc continue delivering strong returnsCPI Data & High Accuracy Swing Entry Alerts - خودرو بانک
What are the future prospects of Imunon Inc.Portfolio Return Report & Daily Profit Maximizing Tips - baoquankhu1.vn
How liquid is Imunon Inc. stock2025 Support & Resistance & AI Powered Market Entry Strategies - beatles.ru
Imunon Inc. Inches Above Key Support — Safe to Hold2025 Buyback Activity & Technical Entry and Exit Tips - beatles.ru
Is Imunon Inc. likely to announce a buybackMarket Performance Report & Low Risk Entry Point Guides - 뉴스영
Why Imunon, Inc. (IMNN) Surged Last Week - MSN
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):